NIH Licenses Super Antibodies to Fight Cancer
Published Date: 7/14/2026
Notice
Summary
The National Institutes of Health is offering new, powerful antibodies for licensing that help the immune system fight cancer better by releasing its natural brakes. This opportunity is perfect for companies ready to bring cutting-edge cancer treatments to market faster, with some international patent options available. Interested parties should act soon to explore this exciting tech and start making a difference—and money!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
NIH Antibodies Available for Licensing
The National Institute of Allergy and Infectious Diseases is offering government-owned pan anti-HLA monoclonal antibodies 3C10 and 15B1 for commercial licensing (HHS Ref. E-005-2026-0). A provisional patent application No. 64/053,946 was filed on April 30, 2026, and foreign patent applications have been filed on selected inventions to extend market coverage.
Pre-Clinical Antibodies Show Strong Activity
The pre-clinical antibodies 3C10 and 15B1 bind MHC-I at a different site than earlier antibodies (DX17 and W6/32), bind over 50 times more strongly, and activate human natural killer (NK) and T cells for tumor control. NIAID notes potential uses alone or with other immunotherapies (including CAR-T or CAR-NK) and possible application to chronic infections like TB, HIV, and hepatitis B or C.
Collaboration Opportunity and Contact
NIAID is seeking parties interested in collaborative research to further develop, evaluate, or commercialize this technology and requests statements of capability or interest. To get more information or access unpublished data you must contact Yogikala Prabhu (tel. 202-365-4785, email: Yogikala.Prabhu@nih.gov) and sign a Confidential Disclosure Agreement.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
Previous / Next Documents
Previous: 2026-14130, Indian Gaming; Approval by Operation of Law of the Wyandotte Nation and State of Kansas Gaming Compact
The Wyandotte Nation and the State of Kansas now have an official gaming agreement that lets the tribe run class III gaming, including sports betting, starting July 14, 2026. Since the government didn’t act within 45 days, the deal automatically got approved by law. This means more gaming options and potential revenue for the tribe and the state, with sports bets placed anywhere in Kansas counting as if made on tribal land.
Next: 2026-14135, David Enright, M.D.; Decision and Order
Dr. David Enright from Maine lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing, so the DEA moved forward and officially revoked his registration. This means he can’t prescribe or manage controlled drugs anymore, effective immediately.